Neuphoria Therapeutics Inc.
Data quality: 100%
NEUP
Nasdaq
Manufacturing
Chemicals
$4.61
▼
$0.09
(-1.91%)
Mkt Cap: 24.85 M
Price
$4.61
Mkt Cap
24.85 M
Day Range
$4.57 — $4.73
52-Week Range
$3.65 — $21.40
Volume
41,265
Open $4.73
50D / 200D Avg
$4.28
7.71% above
50D / 200D Avg
$6.87
32.86% below
Quick Summary
Key Takeaways
Generating 77,229.0 in free cash flow
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-1.33%
Above sector avg (-53.41%)
ROIC-2.82%
Net Margin-2.36%
Op. Margin-7.21%
Safety
Debt / Equity
N/A
Current Ratio11.01
Interest CoverageN/A
Valuation
PE (TTM)
-67.23
Below sector avg (-1.48)
P/B Ratio0.96
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -67.2 | -1.5 |
| P/B | 1.0 | 1.6 |
| ROE % | -1.3 | -53.4 |
| Net Margin % | -2.4 | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | 15.65 M | Net Income (TTM) | -369,632.0 |
| ROE | -1.33% | ROA | -1.10% |
| Gross Margin | N/A | Operating Margin | -7.21% |
| Net Margin | -2.36% | Free Cash Flow (TTM) | 77,229.0 |
| ROIC | -2.82% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 11.01 |
| Interest Coverage | N/A | Asset Turnover | 0.47 |
| Working Capital | 15.54 M | Tangible Book Value | 12.58 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -67.23 | Forward P/E | N/A |
| P/B Ratio | 0.96 | P/S Ratio | 1.59 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | 0.31% | ||
| Market Cap | 24.85 M | Enterprise Value | 7.81 M |
| Per Share | |||
| EPS (Diluted TTM) | -0.23 | Revenue / Share | 2.90 |
| FCF / Share | 0.01 | OCF / Share | 0.01 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | -20.89% |
| SBC-Adj. FCF | -86,543 | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 |
|---|---|---|
| Revenue | 15.65 M | — |
| Net Income | -369,632.0 | -15.49 M |
| EPS (Diluted) | -0.23 | -0.01 |
| Gross Profit | — | — |
| Operating Income | -1.13 M | -17.89 M |
| EBITDA | — | — |
| R&D Expenses | 9.01 M | 9.42 M |
| SG&A Expenses | — | — |
| D&A | 662,890.0 | 662,991.0 |
| Interest Expense | — | — |
| Income Tax | -468,366.0 | -87,320.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 |
|---|---|---|
| Total Assets | 28.59 M | 27.65 M |
| Total Liabilities | 9.59 M | 10.16 M |
| Shareholders' Equity | 19.00 M | 17.49 M |
| Total Debt | — | — |
| Cash & Equivalents | 14.21 M | 12.61 M |
| Current Assets | 15.04 M | 13.19 M |
| Current Liabilities | 4.22 M | 3.83 M |
{"event":"ticker_viewed","properties":{"ticker":"NEUP","listing_kind":"stock","pathname":"/stocks/neup","exchange":"Nasdaq","country":"US"}}